Technical Analysis for INKT - MiNK Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 200 DMA | Bearish | 0.00% | |
| 20 DMA Support | Bullish | 0.00% | |
| 50 DMA Support | Bullish | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Wide Range Bar | Range Expansion | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Crossed Above 200 DMA | Bullish | -7.14% |
| Alert | Time |
|---|---|
| Gap Down Partially Closed | about 20 hours ago |
| Gap Down Closed | about 20 hours ago |
| 60 Minute Opening Range Breakdown | about 20 hours ago |
| Down 5% | about 20 hours ago |
| Down 1 ATR | about 20 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 06/12/2024
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate includes AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Biology Immunology Pharmacy Stem Cell Cell Therapy T Cells Immune Mediated Diseases Natural Killer T Cell Lineage Cell Therapeutics
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Biology Immunology Pharmacy Stem Cell Cell Therapy T Cells Immune Mediated Diseases Natural Killer T Cell Lineage Cell Therapeutics
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.34 |
| 52 Week Low | 0.75 |
| Average Volume | 221,876 |
| 200-Day Moving Average | 1.10 |
| 50-Day Moving Average | 0.96 |
| 20-Day Moving Average | 0.94 |
| 10-Day Moving Average | 0.97 |
| Average True Range | 0.11 |
| RSI (14) | 56.14 |
| ADX | 30.78 |
| +DI | 35.57 |
| -DI | 9.73 |
| Chandelier Exit (Long, 3 ATRs) | 0.97 |
| Chandelier Exit (Short, 3 ATRs) | 1.19 |
| Upper Bollinger Bands | 1.06 |
| Lower Bollinger Band | 0.82 |
| Percent B (%b) | 0.91 |
| BandWidth | 26.22 |
| MACD Line | 0.01 |
| MACD Signal Line | 0.00 |
| MACD Histogram | 0.0151 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.59 | ||||
| Resistance 3 (R3) | 1.62 | 1.46 | 1.50 | ||
| Resistance 2 (R2) | 1.46 | 1.32 | 1.45 | 1.47 | |
| Resistance 1 (R1) | 1.25 | 1.23 | 1.17 | 1.22 | 1.44 |
| Pivot Point | 1.09 | 1.09 | 1.05 | 1.08 | 1.09 |
| Support 1 (S1) | 0.88 | 0.95 | 0.80 | 0.86 | 0.64 |
| Support 2 (S2) | 0.72 | 0.86 | 0.71 | 0.61 | |
| Support 3 (S3) | 0.51 | 0.72 | 0.58 | ||
| Support 4 (S4) | 0.49 |
